Combined evaluation of matrix metalloproteinases and their inhibitors has better clinical utility in oral cancer

Abstract

Background: Oral cancer is a major health hazard worldwide with increasing incidence and mortality. Cervical lymph node metastasis is a major determinant of outcome in oral cancer. The matrix metalloproteinase (MMP) system is critically involved in invasion and metastasis. Assessment of MMPs and tissue inhibitors of MMPs (TIMPs) in certain combinations might have better clinical effcacy given their potential role in the metastatic process. Aim: Plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 in 50 controls and 75 oral cancer patients (nonmeta-static, n=54; metastatic, n=21) were evaluated to assess their investigative value and role in predicting the behavior of this malignancy. Methods: The plasma concentrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 were quantifed by ELISA. The best 2-and 3-marker combinations were calculated using the statistical software mROC. The diagnostic values for all the biomolecules as single markers and their combinations were estimated using the measures of diagnostic accuracy, i.e. the area under the ROC curve and the sensitivity and specifcity at cutoff limits with the highest diagnostic accuracy and at the 95% limits of sensitivity and specifcity, respectively. Results: MMP-9, TIMP-1 and TIMP-2 were signifcantly elevated (p=0.000, p=0.013 and p=0.005, respectively) in oral cancer patients. MMP-9 emerged as the best single statistically signifcant marker in plasma for oral cancer detection. It showed an increase in diagnostic performance when tested in combination with MMP-2 and TIMP-2. The median plasma MMP-9 levels were elevated in both the metastatic and nonmetastatic groups compared with controls (p<0.004 and p<0.007, respectively). Conclusion: The results indicated that plasma MMP and TIMP levels in relevant combinations may facilitate clinical decision-making for improved management of oral cancer patients and may provide important data for selecting patients for treatment with drugs that interfere with MMP and TIMP activities. © 2011 Wichtig Editore.